04th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170020760 | INNER BOWL OF OPERATING HEAD OF NURSING MACHINE, AND NURSING MACHINE - Disclosed is an inner bowl of a working head of a nursing machine, comprising a bowl body, a baffle, and a drying device; the front part of the bowl body is provided with a bowl mouth, the top surface of which is a horizontally arranged drain port, the bottom surface of which is an obliquely arranged U-shaped arc bottom, and both sides of the U-shaped arc bottom of which are uniformly provided with infrared-reflective feces sensors; the outer bottom surface of the bowl body is provided with a urine sensor; the baffle is vertically arranged on the bowl body and is connected to the drain port; the drying device is arranged at the rear side of the bowl body, and an air outlet of the drying device is arranged on the rear side wall of the bowl body below the baffle. Also disclosed is a nursing machine. | 2017-01-26 |
20170020761 | OPERATING TABLE - An operating table includes a patient placement table for placing and securing a patient in a required posture; a main body for supporting the patient placement table; engaging pieces for removably coupling the patient placement table to the main body; and a motor for rotating the patient placement table with a head-feet direction of the patient as a rotation axis to hold the patient placement table at any given rotation angle. | 2017-01-26 |
20170020762 | Method for Treating and Correcting Gait Related Joint Dysfunctions - A method for correcting various dysfunctional joints on a human body using manual manipulation by an practitioner, comprising the steps of first determining the dominant and non-dominant side of a patient's body, manually administering to the human body a primary treatment cycle that includes nine functional joint manipulations each applied on one treatment session sequentially from patient's dominant side foot, the dominant-side knee, the dominant-side hip, the dominant-side pubic symphysis, the dominate side sacrotuberous ligament, the contralateral proximal clavicle, the contralateral shoulder, the contralateral elbow, and ending at the contralateral wrist. After the primary treatment cycle is completed, a secondary treatment cycle comprising nine functional joint manipulations each applied on one treatment session visit sequentially beginning at the non-dominate foot and moving upward and towards the patient's upper body contralateral shoulder, arm and wrist. After the secondary treatment cycle is completed, the primary treatment cycle is repeated. | 2017-01-26 |
20170020763 | Therapeutic System and Method for Flexing and Extending Metacarpal and Phalangeal Joints - A therapeutic system and method flexes, extends, and exercises the metacarpal and phalangeal joints of an affected hand. The system comprises a therapeutic glove that receives an affected hand and adjustably applies movement to the fingers and thumb in a first forward direction to form a flexion position, and a second rearward direction to form an extension position. The position of the fingers and thumb as well as the amount of pressure applied is controlled by manipulating restraining members to pull and restrain the fingers and thumb and then attaching to a corresponding body and wrist portion on the glove. The extent of the pulling, including the pressure applied to the metacarpal and phalangeal joints, is fixed, adjustable, and easily releasable. A secondary therapeutic glove compensates for the tactile perception feedback from an unaffected hand. A therapeutic pain relief modality is applied prior to donning the glove. | 2017-01-26 |
20170020764 | Walker standing aid accessory - A walker standing aid accessory package consists of a lower attachment and an upper attachment. The lower foot bar piece allows the caregiver to utilize body weight to pin the walker's front legs to the floor or ground surface securely. The upper part incorporates multiple hand placement stabilization choices for both the patient and the caregiver. This invention increases patient's self help and reduces most of the caregiver's exertion. Once the patient is standing upright, the caregiver may step aside and monitor said patients immediate ambulation. The accessory package converts an existing walker into a device that not only helps the patient to stand but also reduces the strain on the caregiver. The walker with the accessories installed offers no interference or compromise to the existing walker's integrity, mobility or storage. | 2017-01-26 |
20170020765 | WALKING ASSISTANCE METHOD AND APPARATUSES PERFORMING THE SAME - A walking assistance method may include receiving at least one abnormal gait type selected from a plurality of abnormal gait types, and differently controlling a walking assistance apparatus based on the at least one abnormal gait type. | 2017-01-26 |
20170020766 | METHOD OF RESTORING BINOCULAR FUSION AND STEREOPSIS - A method of restoring binocular fusion and stereopsis in a patient exhibiting a functional scotoma includes determining that the patient has a treatable scotoma, presenting an object to be viewed by the patient, placing an eyewear apparatus with a right lens and a left lens in front of the patient's eyes, and treating the scotoma by alternately and sequentially occluding the right lens and the left lens at a frequency of 0.5-10 Hz when the patient's gaze is fixed on the object. | 2017-01-26 |
20170020767 | BASALT SLEEP MASK - A sleep mask is provided for. This sleep mask preferably features a nose bridge which has at least one substantially hollow chamber and two inner sections which each have a first part and a second part. The first part has a non-uniform height and an inner volume, and the second part has a smaller volume than the first part. The sleep mask also features two outer sections, each of which have a height and a pocket, where each of the two outer sections envelopes one of the two inner sections and is attached to the nose bridge. The substantially hollow chamber, the inner volume of the two inner sections, and the pocket of the two outer sections is filled with a granular material, which is preferably pulverized igneous basalt rock. | 2017-01-26 |
20170020768 | Neonatal Chest Splint for Applying Negative Distending Pressure - The present invention relates to devices and methods for assisting breathing in a subject. In one embodiment, the device of the present invention is a splint that can be used to apply negative distending pressure, i.e., outward pull, to one or both of the chest walls and/or the abdomen of a subject. In certain embodiments, the splint comprises an air bladder that can be attached to the skin of the subject's chest and/or abdomen. When the air bladder is inflated, negative distending pressure is applied to the subject's chest and/or abdomen, thereby assisting or promoting respiration. In another embodiment, the splint comprises a piezoelectric material that when activated can provide negative distending pressure to the subject's chest and/or abdomen. In another embodiment, the subject is a neonate. In another embodiment, the inflated air bladder can apply a compressive force on the chest to facilitate expiration, and the removal of secretions in the airways. | 2017-01-26 |
20170020769 | CUSHION SUPPORT INSERT - A cushion support insert is described generally having a cushion with a surface sized for placement beneath a body of a user, the surface defining at least a first channel and a second channel therein. A fluid-filled bladder may be sized for placement upon the surface and a first plurality of pods and a second plurality of pods may be positioned upon or beneath opposing ends of the fluid-filled bladder such that the first plurality and second plurality are retained respectively within the first channel and the second channel. Each of the pods may be fluid-filled and aligned adjacent to one another within a respective first covering and second covering. | 2017-01-26 |
20170020770 | COMPRESSION DEVICE FOR THE FOOT - A compression device for the foot comprising: a wrap adapted to surround the foot, the wrap comprising at least two bladders which when inflated conform to the shape of the foot to provide compression, the bladders being positioned on the wrap so that a first bladder focuses compression on the heel of the foot and a second bladder focuses compression on the arch of the foot; a channel attached to each bladder for independently delivering fluid to each bladder; and a controller attached to the channels that generates and independently controls the flow of fluid to the bladders. | 2017-01-26 |
20170020771 | INTERCHANGEABLE MASSAGE ROLLER SYSTEM - A massage roller system includes an axle and a massage roller rotatably mounted on the axle such that first and second ends of the axle protrude from first and second end surfaces of the massage roller. First and second handles are mounted to the first and second ends of the axle, each handle including a knob that, in response to twisting, adjusts pressure applied by the handle to one of the first and second end surfaces of the massage roller. First and second supportive plates each include a bearing surface for supporting the first and second handles. | 2017-01-26 |
20170020772 | THERAPEUTIC SYSTEMS AND ROLLER DEVICES AND METHODS OF USE - Roller devices, systems, and methods for their use to treat or alleviate symptoms relating to soft tissue injuries and ailments. Such a therapeutic system includes at least one roller device that has an axis of rotation and at least first and second rollers oriented perpendicular to the axis of rotation and spaced apart along the axis of rotation to provide substantially continuous lines of contact with an individual's skin. Each of the rollers has a circular perimeter that defines an outer diameter and a contact surface of the roller. The contact surface defines a contact surface radius sized so that the roller applies a level of pressure to the soft tissue beneath the skin when the roller device is pressed with a level of force against the skin of the individual and caused to travel across the skin within the body region of the individual's body. | 2017-01-26 |
20170020773 | Massage Roller - A massage apparatus includes at least one roller. The roller includes a tubular frame, raised rolling bands, and a plurality of massaging protuberances, wherein the height of the bands is at least the height of the protuberances. The bands and protuberances may be flexible and pliable, and made from rubber, silicone, neoprene or foam. A removable cap may be provided. | 2017-01-26 |
20170020774 | THERAPEUTIC ROLLER - A thermally active roller apparatus, which includes a core; an intermediate compliant layer disposed about the core; a cover disposed about the intermediate compliant layer; and a heating element. Included is a thermally active roller apparatus in which the compliant layer may be formed from two or more portions having different stiffnesses. A thermally active or non-thermally active roller apparatus that includes a compliant layer comprising at least two portions of different stiffnesses and wherein the at least two portions are interdigitated to lock them together. | 2017-01-26 |
20170020776 | RESPIRATORY THERAPY SYSTEMS, SENSORS ARRANGEMENTS AND METHODS - A respiratory therapy system includes a vibratory expiratory therapy device through which the patient exhales to set up vibrations within the chest. An array of piezoelectric vibration sensors is mounted on the patient's chest and supplies vibration outputs to a processor, which in turn provides an output to a display indicative of impedance of different regions of the chest. | 2017-01-26 |
20170020777 | VIBRATION GENERATING UNIT, VIBRATING BODY UNIT AND ULTRASONIC TREATMENT INSTRUMENT - A vibration generating unit includes an element unit, and the element unit includes a piezoelectric element generating an ultrasonic vibration by being supplied with electric power. A proximal-side fixing member abuts on the element unit from a proximal direction side and a distal-side fixing member abuts on the element unit from a distal direction side such that the element unit is sandwiched between the proximal-side fixing member and the distal-side fixing member in a longitudinal direction. The distal-side fixing member has a greater acoustic impedance than the proximal-side fixing member. | 2017-01-26 |
20170020778 | A MACHINE AND A METHOD FOR FASCIA TREATMENT - The handheld machine and method are for the treatment of fascia deficiencies on human beings and animals. The machine has a motor driver and a motor driven to produce a wave cam through a cam transmission operating on a plunger thrusting back and forth in predetermined low frequencies. | 2017-01-26 |
20170020779 | MONITORING AND FEEDBACK FOR RESUSCITATION - A method, a system, or an apparatus for resuscitation can include a first sensor having a first output configured to provide a first sensor signal corresponding to optical attenuation of tissue at a site. The method, the system, or the apparatus can include a processor coupled to the first output. The processor can be configured to generate an output signal. The output signal can be determined based on a first parameter of the optical attenuation. The first parameter can correspond to blood circulation associated with externally applied stimulation of a cardiovascular organ. The method, the system, or the apparatus can include a system output coupled to the processor. The system output can be configured to provide a control signal determined using the output signal. | 2017-01-26 |
20170020780 | MULTI-PUMP HOT TUB PLUMBING SYSTEM - A hot tub plumbing system is provided, the system including a plurality of water pumps respectively provided at different sides of a hot tub having a plurality of jets, and a plurality of manifolds each having an intake port coupled to one of the water pumps, and each configured to have a plurality of output ports respectively connected by tubing to one of the jets of the hot tub. | 2017-01-26 |
20170020781 | FACIAL STEAMING DEVICE - A facial steaming apparatus includes a base, a water box and a steam spray head. The base has a steamed object receiving cavity, a water box cavity, a plurality of pores at a bottom wall of the steamed object receiving cavity, and a steam generator. The water box is detachably assembled with the base and located in the water box cavity. The steam spray head is detachably assembled with the base and has a steam outlet in communication with the steamed object receiving cavity. By means of the design that steam spray head is detachable and the base has the steamed object receiving cavity to receive a to-be-steamed object, the facial steaming apparatus of the present disclosure can provide the user to steam face by the steam containing component of fruit or vegetable. | 2017-01-26 |
20170020782 | ELONGATED STEAMHEAD FOR A STEAM BATH - The dispensing chamber of the steamhead is mounted between the studs within the wall of a steam bath enclosure. The chamber is isolated from the environment and includes an elongated steam outlet extending outwardly from the chamber, through an opening in the wall. The rectangular outer edge of the outlet is flush with the interior surface of the wall and is the only portion of the chamber visible from inside the enclosure. The outer edge of the outlet is shaped to coordinate with the appearance of a linear drain. It also allows the steam to be dispensed over a wider area. The outlet has a steam flow capacity greater than the steam flow capacity of the inlet such that steam expands within the chamber as the velocity of the steam is reduced. Internal baffles reduce noise. Light sources may be associated with the chamber. | 2017-01-26 |
20170020783 | Delivery of Medicine or Other Therapy Orally - Among other things, a container has a chamber and an open end of the chamber. The container is configured at the open end to be surrounded by lips of a user to permit the user to apply suction to the chamber through the open end. A gelled dose of a therapeutic agent in the chamber is in contact with a wall of the chamber and is between the wall of the chamber and the open end. There is at least one hole in the wall for air to reach the gelled dose when the user is applying the suction to the chamber to release the gelled dose into the user's mouth. A mechanism prevents contamination of the gelled dose through the hole in the wall until the user is ready to consume the gelled dose and permits air to reach the gelled dose through the holes when the user is ready to consume the gelled dose. | 2017-01-26 |
20170020784 | POOLING DEVICE FOR SINGLE OR MULTIPLE MEDICAL CONTAINERS - A device is provided for pooling a fluid from a container unit having at least one container, and includes an inlet port having at least one inlet channel configured for receiving the fluid or ambient air, and an outlet port having at least one outlet channel configured for delivering the fluid to an attachment. Both inlet and outlet ports are disposed on the device. A cavity is provided for accommodating insertion of the container unit for pooling the fluid from the at least one container. At least one spike is disposed in the cavity and configured for puncturing a stopper of the at least one container when the container unit transitions from an upper position to a lower position. | 2017-01-26 |
20170020785 | Medical Administration and Information System - A System for storing pills in their original pharmaceutical bottles, verifying authenticity and pill count of each medication, tracking inventory, ordering refills, dispensing pills at prescribed times, providing alerts to caregivers, and reporting adherence patterns to medical providers, institutions, companies and interested parties through its Analytics system. The System accomplishes functions while displaying informational content on its touch-screen display, while showing advertisements, health recommendations, information on drug interactions, side effects, and related content on the System Device's touch-screen. | 2017-01-26 |
20170020786 | ELECTROLYTE CAPSULE DISPENSER - A system is delineated for dispensing capsules used to provide desired material to a user engaged in activity, athletic or otherwise. The system may include a housing and a magazine slideably retained within the housing, wherein the magazine is for retaining provided capsules for selective dispensing from the housing. The system may also include a timer for counting down a predetermined time period and an indicator for signifying to a user when the predetermined time period has run, indicating that it is time to dispense and consume one of the provided capsules. | 2017-01-26 |
20170020787 | Infant Bottle with Formula Timer - A infant bottle provides a timer to alert the user when an hour has elapsed. The infant bottle provides an endcap with a ring of LED lights around the base of the bottle, and a recessed button in the center of the bottom surface. Pressing the button once activates a one-hour timer. When the hour expires, the LED lights flash on and off until the button is pressed twice. Pressing the button twice at any time deactivates the timer. The endcap is easily removed for the purpose of placing the bottle in a dishwasher for cleaning. | 2017-01-26 |
20170020788 | Lullaby Pacifier - The invention disclosure relates to a baby pacifier. The pacifier disclosed herein has a built-in memory system, Bluetooth device, audio system, and control switch. The pacifier is meant for imparting soothing and comforting feelings to the child once it uses the pacifier via an audio system. The pacifier, once activated, is capable of producing music, stories, poems, and a parent's voice via the audio system. The pacifier increases the learning capabilities of a child through the activation of the auditory stimulus. | 2017-01-26 |
20170020789 | RESTORATIVE RESIN COMPOSITIONS AND METHODS OF USE - Embodiments of the invention are directed to dental compositions comprising: (1) at least one cationically reactive compound; (2) at least one cationic photoinitiator; (3) at least one compound which is: an organic monomer, oligomer or polymer, said compound comprising at least one reactive oxirane, oxetane, or alkenyl ether, (4) at least one compound which is: an organic monomer, oligomer or polymer, said compound comprising at least one reactive acrylate that is capable of forming an interpenetrating network; (5) at least one free radical initiator; and (6) at least one compound which is: an organic monomer, oligomer or polymer, said compound comprising at least one reactive acrylate or methacrylate and at least one oxirane, oxetane, or alkenyl ether. | 2017-01-26 |
20170020790 | STERILIZABLE DENTAL ROOL CANAL FILLING COMPOSITION, POINTS/CONES MADE OF SAME, AND PROCESS OF STERILIZING SAME - A root canal filling cone made of a material having a composition that can maintain its physical and chemical characteristics and shelf life after sterilization, and a process of sterilizing the point/cone prior to shipment to a user. In one aspect, the cone is made of a composition that includes a plurality of base polymers of substantially equal amounts, and nanoparticles, which can withstand sterilization by gamma irradiation. In one embodiment, the compound includes Gutta Percha based polymers. In another aspect, the Gutta Percha based cone is packaged and sterilized by irradiation prior to shipment to a user. In one embodiment of the present invention, the irradiation is gamma irradiation. | 2017-01-26 |
20170020791 | ADHESIVE DENTAL MATERIALS WITH STRONGLY ACIDIC ADHESIVE POLYMERS - Radically polymerizable dental material which contains at least one radically polymerizable oligomer or polymer with strongly acidic groups, which has a number-average molecular weight of 1,000 to 200,000 g/mol. | 2017-01-26 |
20170020792 | SOLID COMPOSITION WITH A VINYL POLYMER BEARING A CARBOSILOXANE DENDRIMER UNIT AND VOLATILE HYDROCARBON-BASED OILS, AND TREATMENT PROCESS - The present invention relates to an anhydrous solid cosmetic composition comprising: •a) at least one vinyl polymer comprising at least one carbosiloxane dendrimer-based unit; •b) at least two hydrocarbon-based volatile oils, •c) at least one saturated or unsaturated, preferably linear, solid fatty alcohol whose melting point is greater than or equal to 40° C., comprising from 16 to 60 carbon atoms. The invention also relates to a process for making up and/or caring for the lips, in which the abovementioned composition is applied to the lips. | 2017-01-26 |
20170020793 | PERSONAL WASH COMPOSITION - The present invention relates to personal wash compositions, in particular shampoo compositions comprising beneficial oils. It has been a long felt need to solubilise beneficial oils such as mineral oil in wormlike micelles in surfactant systems. It is therefore an object of the present invention to provide a personal wash composition comprising functional levels of beneficial oil such as mineral oil. It has been found that mineral oil can be solubilised in wormlike micelles in a surfactant system with specific hydrophilic or lipophilic linker molecules. | 2017-01-26 |
20170020794 | AGENT CONTAINING MICROCAPSULES - The application relates to a method of using cleaning agents, and fabric treatment agents containing a combination of at least two different microcapsules as well as to methods for releasing active substances from said microcapsules when using said agents. | 2017-01-26 |
20170020795 | METAL SALT COMPOSITIONS - Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same. | 2017-01-26 |
20170020796 | COSMETIC USES OF SWERTIAMARIN - The present invention relates to the uses of swertiamarin or of a plant extract enriched with swertiamarin, for stimulating the formation or regeneration of the epidermis and/or for stimulating the metabolism of the dermis mainly in the cosmetics field. | 2017-01-26 |
20170020797 | COMPOSITION - A composition that is useful in a skin function improving agent includes at least a sapogenol, and a collagen hydrolysate. This composition can be used in a skin function improving agent and is particularly useful in a skin function improving agent for inhibiting transdermal moisture loss and/or for retaining the moisture in the stratum corneum. | 2017-01-26 |
20170020798 | HESPERIDIN-CONTAINING COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS - Compositions and methods for treating aged skin or skin otherwise suffering from abnormal epidermal barrier function are disclosed, where the compositions include hesperidin. | 2017-01-26 |
20170020799 | TOPICAL DELIVERY OF SKIN COMPOSITIONS HAVING LOW PH - Low pH compositions for topical administration to skin are provided. They comprise a buffering agent having a pKa of about 2.8 to about 4.2 and a cosmetically acceptable active ingredient having a pKa within about 1 unit of the pKa of the buffering agent. The composition has a pH of about 3.3 to 4 and a buffer capacity of at least about 0.15. A method of increasing the topical delivery of a cosmetically acceptable active ingredient having a pKa of about 2.8 to about 4 is also provided. | 2017-01-26 |
20170020800 | ORAL COMPOSITIONS - An oral composition is described. The oral composition can include a solvent comprising water and a cosolvent chosen from lower alkyl alcohols, acetone and a combination thereof, and an acidic copolymer comprising of carboxylic acid monomeric units. The acidic copolymers can be dissolved in the oral composition and the oral composition can form a film on a surface when contacted with an aqueous solution. | 2017-01-26 |
20170020801 | Oral Care Compositions - The application discloses dentifrice compositions comprising arginine together with fluoride, phosphate and pyro-phosphate salts, in a dentifrice base with a calcium-free silica abrasive, which compositions provide enhanced remineralization, together with methods of using and of making these compositions. | 2017-01-26 |
20170020802 | NATURAL COMPOSITION - A natural composition comprises a plurality of ingredients that are mixed in predetermined percentages to formulate a natural, healthful, and flavorful composition that integrates into at least one consumable item to produce a flavorful, healthful enhanced consumable item. The ingredients of the composition include a Frankincense oil, a gum, and a fruit aroma compound. The ingredients are mixed together in varying weight percentages for a desired outcome when integrated with the consumable item. The combination of ingredients creates a synergy that enhances the consumable item. The composition is mixed, dissolved, distilled, or ground with the consumable item. The consumable item may include a tobacco, a charcoal briquette, an energy drink, mineral water, butter, a mouthwash, and toothpaste. | 2017-01-26 |
20170020803 | TREATMENT AND COMPOSITION FOR ACHIEVING SKIN ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION - Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing a combination of a cationic surfactant such as N,N,-dimethyldodecyl amine oxide (DMDAO), an anionic surfactant such as sodium dodecyl sulfate (SDS), or monoalkyl phosphate (MAP) and a chelating agent such as ethylene diamine tetraacetate (EDTA) to stimulate a chronic increase in the replacement rate of the skin's stratum corneum by means of corneum protease activation. This chronic, low level stimulation is effective to induce repair and replacement of the stratum corneum, epidermis, and dermis of the skin and improvements in the appearance, function, and anti-aging properties of the skin. | 2017-01-26 |
20170020804 | METHOD OF IMPROVING THE APPEARANCE OF AGING SKIN - A stable skin care composition for improving the appearance of aging skin is disclosed. The stable skin care composition that includes an effective amount of artichoke leaf extract and carob fruit extract that, in combination, can provide a synergistic increase in the up-regulation of key epidermal-associated genes related to skin aging, and thereby provide an improvement in the appearance of aging skin. The stable skin care composition is substantially free of complexing agents and includes sunscreen agents to help photostablize the composition. | 2017-01-26 |
20170020805 | CORDYCEPS CONTAINING TOPICAL SKIN CARE FORMULATION - The present disclosure relates to extracts of | 2017-01-26 |
20170020806 | COSMETIC COMPOSITIONS AND USES THEREOF - Disclosed is a method for reducing the appearance of cellulite or improving the texture of skin in a target region of skin that has cellulite or rough skin texture, the method comprising topically applying a composition to the target region that includes an effective amount of a mixture of caffeine, escin, and an aqueous-alcoholic extract from | 2017-01-26 |
20170020807 | PREPARATIONS FOR SUPPRESSING OR ATTENUATING OCULAR IRRITANCY - Provided is a tear-free formulation for suppressing or reducing ocular irritancy of a pre-made cosmetic or therapeutic formulation or an ophthalmic formulation suitable for application to an eye of a subject or to a skin region surrounding an eye of a subject. | 2017-01-26 |
20170020808 | TOPICAL SKIN FORMULATIONS - The present invention relates generally to methods and compositions useful for application to skin and hair comprising saccharide isomerate, | 2017-01-26 |
20170020809 | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS - Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject. | 2017-01-26 |
20170020810 | Nutritional Supplement and Method of Administering the Same - A nutritional supplement that improves energy levels in a human being and a method of administering the same to provide enhanced energy is described. The nutritional supplement comprises fat, caffeine, vitamins and minerals enveloped and surrounded in an edible protective coating. In preferred embodiments, the nutritional supplement is a composition including a fatty matrix supporting caffeine, B vitamins and vitamin D, the fatty matrix is comprised of dark chocolate and the edible protective coating is a sugar shell. The caffeine in the supplement provides for enhanced energy, vitamin D helps to maintain muscle function and strength and supports mental health, and B vitamins facilitate conversion of food or stored energy into active energy. The fatty matrix and edible protective coating cooperate to preserve the nutritional supplement without the need for artificial preservatives. The fatty matrix and edible protective coating further provide for delivery and improved bioabsorption of the caffeine and vitamins to a human ingesting the food product. The composition also may include L-Theanine to assist in tempering the anxiety-inducing effects of caffeine such as jitteriness and masking agents to mask the bitterness of the caffeine, vitamins and minerals. The method comprises administration of the nutritional supplement as described to improve energy levels in a human being. | 2017-01-26 |
20170020811 | COMPOSITIONS AND METHODS FOR COMBINATION INGREDIENT DELIVERY - Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. | 2017-01-26 |
20170020812 | MEDICAL CHEWING GUM - The invention relates to a medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient, the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and -80% by weight of vinyl laurate-vinyl acetate copolymer, and wherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin. | 2017-01-26 |
20170020813 | CATIONIC DRY POWDERS - The invention relates to respirable dry particles that contain one or more divalent metal cations, such as magnesium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent. | 2017-01-26 |
20170020814 | SINGLE SERVE BEVERAGE POD CONTAINING CANNABIS - Single-serve containers for use in brewing a cannabis-based beverage are described, as are methods for preparing a single-serve container configured for receipt in a single-serve brewing machine. The method includes: adding a processed cannabis product to the single-serve container; adding, to the single-serve container, at least one of an extraction or flavoring agent; and sealing the single-serve container. | 2017-01-26 |
20170020815 | DIETARY SUPPLEMENT FOR IMPROVING BRAIN HEALTH - Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises Inositol, N-Acetyl L-Tyrosine, pyrroloquinoline quinone (PQQ), Choline bitartrate, L-Theanine and Acetyl-L-Carnitine. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health. | 2017-01-26 |
20170020816 | TARGETED POLYMERIZED NANOPARTICLES FOR CANCER TREATMENT - The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers. | 2017-01-26 |
20170020817 | SOLID NANOPARTICLE FORMULATION OF MICROTUBLE INHIBITORS WITH REDUCED OSTWALD REPENING FOR ORAL ADMINISTRATION - The present invention belongs to the fields of pharmacology, medicine and drug delivery. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles comprising microtubule inhibitor such as docetaxel, cabazitaxel and ixabepilone with reduced Ostwald ripening for oral administration. | 2017-01-26 |
20170020818 | CARBOXYLVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 2017-01-26 |
20170020819 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS - This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides. | 2017-01-26 |
20170020820 | Tamper Resistant Solid Oral Dosage Forms - Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. | 2017-01-26 |
20170020821 | FORMULATION OF SYK INHIBITORS - Disclosed are pharmaceutical compositions comprising a compound having the formula: | 2017-01-26 |
20170020822 | EXTENDED RELEASE ABUSE DETERRENT LIQUID FILL DOSAGE FORM - The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form. | 2017-01-26 |
20170020823 | METHOD FOR PREPARING POLYMERIC MICROSPHERES CONTAINING DRUG - The present invention relates to a method for preparing polymeric microspheres to improve the drug encapsulating efficiency and, more specifically, to a method for preparing polymeric microspheres, the method comprising the steps of: preparing an internal water phase (w1) and an oil phase (0); mixing the internal water phase and the oil phase to prepare a W1/0 emulsion, followed by cooling; mixing the W1/0 emulsion with an external water phase (W2) to prepare a W1/0/W2 emulsion; and drying the prepared W1/0/W2 emulsion, followed by collection. The method of the present invention can increase the drug encapsulating efficiency and manufacture polymeric microspheres having high drug contents through a procedure of maintaining the step of solidifying the oil phase at a particular temperature for a particular period of time, and thus the method of the present invention is effective in the preparation of sustained release-type drugs. | 2017-01-26 |
20170020824 | METHODS OF TREATING PANCREATIC CANCER - Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine. | 2017-01-26 |
20170020825 | NOVEL FORMULATIONS OF VOLATILE ANESTHETICS AND METHODS OF USE FOR REDUCING INFLAMMATION - The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site. | 2017-01-26 |
20170020826 | STABILIZATION OF ALCOHOL INTOXICATION-INDUCED CARDIOVASCULAR INSTABILITY - The present invention concerns use of an agent that increases sphingosine-1-phosphate (S1P) receptor activity, such as S1P, or an S1P receptor agonist, for treatment of alcohol-intoxicated subjects will help stabilize blood pressure and improve resuscitation efforts in alcohol-intoxicated subjects, including alcohol-intoxicated trauma patients. Another aspect concerns a kit for stabilization of alcohol-intoxicated subjects, comprising an agent that increases S1P receptor activity. | 2017-01-26 |
20170020827 | EPINEPHRINE FINE PARTICLES AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE - The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. | 2017-01-26 |
20170020828 | Use of Disulfiram for Inflammatory Breast Cancer Therapy - Methods, compositions of matter, and kits for treatment of breast cancer, and in particular for inflammatory breast cancer, in a patient are disclosed. The methods can include administering a redox modulating agent to the patient. The redox modulating agent can be disulfiram. | 2017-01-26 |
20170020829 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 2017-01-26 |
20170020830 | ODOR FREE MILK PRODUCTION ENHANCERS FOR RUMINANTS - A feed supplement for ruminants to increase milk production, comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid. | 2017-01-26 |
20170020831 | ODOR FREE VOLATILE FATTY ACIDS AS AN ENERGY SOURCE FOR RUMINANTS, SWINE AND POULTRY - A feed supplement energy source for ruminants, swine and poultry comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid. | 2017-01-26 |
20170020832 | PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOF - This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit. | 2017-01-26 |
20170020833 | METHOD FOR TREATING AND/OR PREVENTING ACNE SCARS WITH A FIXED COMBINATION OF ADAPALENE OR ITS SALTS AND BENZOYL PEROXIDE - A method is described for treating and/or preventing acne scars wherein an effective amount of a composition including a fixed combination of adapalene or a salt thereof and benzoyl peroxide is administrated to a patient in need thereof. | 2017-01-26 |
20170020834 | PROPHYLACTIC USE OF NEUROPROTECTANTS IN SPORTS-RELATED TRAUMATIC BRAIN INJURY - Dietary supplements for reducing damage to brain cells characterized by loss of brain cells or loss of brain cell function in patients that have suffered from traumatic brain injury (“TBI”) while participating in sports and/or other athletic events are disclosed herein. The Nutraceutical compositions offer possible ameliorating effects for the secondary phase of TBI. Creatine, vitamin E, zinc, magnesium, DHA, and lipoic acid, taken together, offer a prophylactic measure to ameliorate brain damage that occurs during the secondary phase of SRTBI. | 2017-01-26 |
20170020835 | INOS-INHIBITORY COMPOSITIONS AND THEIR USE AS BREAST CANCER THERAPEUTICS - Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular. | 2017-01-26 |
20170020836 | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease - The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof. | 2017-01-26 |
20170020837 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE - Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed. | 2017-01-26 |
20170020838 | TREATMENT FOR RESPIRATORY DISEASE - The present invention relates to a family of amidino compounds in combination with a hyperosmotic agent or a purinergic agonist for use in a method of treating respiratory disease. More specifically the invention relates to 6-amidino-2-napthyl 4-guanidinobenzoate in combination with a hyperosmotic agent or a purinergic agonist for use in a method of treating respiratory disease such as cystic fibrosis. | 2017-01-26 |
20170020839 | Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 2017-01-26 |
20170020840 | SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS - The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. | 2017-01-26 |
20170020841 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE - A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated. | 2017-01-26 |
20170020842 | ANTI-NEUROINFLAMMATORY AND PROTECTIVE COMPOUNDS IN ACHILLEA FRAGRANTISSIMA - The invention relates to 3,5,4′-trihydroxy-6,7,3′-trimethoxyflavone (TIF) and achillolid A in prevention or treatment of Alzheimer's disease as well as other neurodegenerative diseases such as Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), ischemia, immunodeficiency virus-1 (HTV-1)-associated dementia, Lewy body associated dementia, traumatic brain injury (TBI), glioma, epilepsy. Huntington's disease, multiple sclerosis, glaucoma and schizophrenia where neuroinflammation, oxidative stress, glutamate toxicity and amyloid beta toxicity are part of the pathophysiology. | 2017-01-26 |
20170020843 | DEUTERATED BENZOPYRAN COMPOUNDS AND APPLICATION THEREOF - The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors. | 2017-01-26 |
20170020844 | COMPOSITION AND METHOD FOR RAPIDLY INDUCING AN ENDOGENOUS KETOSIS - A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip. | 2017-01-26 |
20170020845 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2017-01-26 |
20170020846 | COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF MULTI-DRUG RESISTANT MICROBES - Compositions and methods for preventing and treating infection with multi-drug resistant bacteria with AR-13 alone or in combination with antibiotics are provided. | 2017-01-26 |
20170020847 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS - The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof. | 2017-01-26 |
20170020848 | EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF - This invention relates to extended release injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer, and a solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the extended release injectable formulations of the invention to the animal in need thereof. | 2017-01-26 |
20170020849 | PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF - This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 2017-01-26 |
20170020850 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors - The present invention is directed to arylpyrrolopyridine derivatives of Formula A: | 2017-01-26 |
20170020851 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST - Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). | 2017-01-26 |
20170020853 | Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System - Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease. | 2017-01-26 |
20170020854 | PRIDOPIDINE BASE FORMULATIONS AND THEIR USE - This invention provides modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine base, and at least one pharmaceutically acceptable rate controlling excipient. | 2017-01-26 |
20170020855 | Methods and Compositions for Treating Vasomotor Symptoms - The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject. | 2017-01-26 |
20170020856 | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use - The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention | 2017-01-26 |
20170020857 | TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 2017-01-26 |
20170020858 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2017-01-26 |
20170020859 | 6-ALKYNYL-PYRIDINE DERIVATIVES - 6-Alkynyl-pyridine of general formula (I) | 2017-01-26 |
20170020860 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 2017-01-26 |
20170020861 | DRUG TREATMENT OF OVERACTIVE BLADDER - Provided are methods of treating an overactive bladder in a patient which include: administering a Myosin II ATPase inhibitor compound; or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2,3b] quinolin-4-one) compound of Formula 1 or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2,3b] quinolin-4-one) compound of Formula II; or administering pharmaceutically-acceptable salts, racemic mixtures, enantiomers, or prodrugs of said compounds, useful in their active form as inhibitors of Myosin II ATPase related to over-active bladder. Optionally the compounds are administered intervesicularly into the bladder. Also provided are pharmaceutical compositions comprising said compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder related to inhibition of Myosin II ATPase. These pharmaceutical compositions also may contain one or more other compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder. | 2017-01-26 |